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Abstract 
      Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Standard 
therapeutic approaches provide modest improvement in the progression-free and overall survival, 
necessitating the investigation of novel therapies. We review the standard treatment options for GBM and 
evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of 
angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment 
with low voltage electric fields.
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      With a yearly incidence of 3/100,000-4/100,000, glioblastoma 
multiforme (GBM) is the most common malignant primary brain tumor 
in adults. Despite modern treatments with the current standard of 
care, the outcome of GBM patients remains poor with a median life 
expectancy of 15-17 months[1]. Fewer than 16% of patients survive 
more than 3 years[2]. Novel therapeutic approaches are needed to 
improve the outcome of these patients. An improved understanding 
of molecular biology and cancer genomics has led to the identification 
of a number of mutated genes and abnormalities in signaling 
pathways. The key role of the microenvironment, especially of tumor 
angiogenesis, has also been elucidated and may provide avenues 
for future therapeutic options. This review focuses on the current 
standards of care and highlights novel therapeutic approaches for the 
treatment of GBM.
Current Standard Treatment Options
for GBM
      GBMs are highly invasive tumors that are surrounded by 
peritumoral edema and inflammation. Due to their highly aggressive 
nature, the tumor margins of GBMs are unclear, and GBMs are 
therefore usually not amenable to complete resection. Nevertheless, 
surgical resection remains the first step in the management 
of GBM to the extent that it is safely feasible. Tumor resection 
allows for pathologic confirmation of the diagnosis and relieves 
compressed brain structures (Figure 1). As of 2005, the addition of 
chemotherapy to radiation has become the first-line treatment for 
GBM. Temozolomide (TMZ, Temodal, Temodar®, MSD, Merck & 
Co, Whitehouse Station, NJ, USA), an alkylating cytotoxic agent, is 
administered orally on a daily basis at a dose of 75 mg/m2 throughout 
radiotherapy. Four weeks later, magnetic resonance imaging (MRI) is 
repeated, and TMZ is then given at a dose of 150-200 mg/m2 daily 
for 5 days every 28 days for maintenance. MRIs are performed after 
every 2-3 cycles of TMZ treatment to ensure continuous stability 
or response of the tumor to treatment (Figure 2). In comparison 
to radiotherapy alone, in a large, randomized phase III trial, TMZ 
treatment along with radiotherapy resulted in an improved median 
overall survival (OS) from 12.1 to 14.6 months and an increase in the 
2-year survival rate from 10% to 27%[1,3], and this finding has since 
been confirmed by additional reports. In an unplanned analysis of a 
representative subgroup of patients, it was shown that the addition 
of TMZ mainly benefited patients with a methylated O-6-methyl- 
guanine-DNA methyltransferase (MGMT) gene promoter[4]. MGMT is 
a DNA repair protein that reverses the damage induced by alkylating 
chemotherapy agents. Methylation of the gene promoter results in 
decreased expression of this enzyme and thus renders tumor cells 
more susceptible to alkylating agents.
      As elderly patients with GBM are considered to have a particularly 
poor prognosis, many clinical trials have been restricted to patients 
less than 65-70 years of age. The benefit of radiotherapy in elderly 
patients was confirmed in a randomized trial comparing radiotherapy 
to best supportive care alone. The median OS increased from 3.9 to 
6.9 months with radiotherapy and resulted in a better quality of life[5]. 
For elderly patients, hypofractionated radiotherapy administered over 
15 days (34 Gy in 3.4 Gy fractions[6] or 40 Gy in 15 daily fractions 
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Figure 1. T1 post gadolinium sequence 
of magnetic resonance imaging (MRI) 
of a 46-year-old patient with a butterfly 
glioblastoma multiforme (GBM) invading the 
corpus callosum.
of 2.6 Gy[7]) was shown to result in equivalent outcome to standard 
radiotherapy (30 fractions of 2 Gy)[7]. Two recent phase III studies 
with the objective of avoiding radiation-induced toxicity and allowing 
for an easy and better tolerated oral treatment for more vulnerable 
elderly patients compared radiotherapy with TMZ chemotherapy 
alone. These 2 trials showed that in elderly patients, there was no 
significant difference in the outcome of patients undergoing standard 
radiotherapy, hypofractionated radiotherapy, or TMZ alone. However, 
Figure 2. The standard treatment regimen for GBM that combines radiotherapy (RT) with temozolomide (TMZ).  *Prophylaxis 
against Pneumocystis Jirovecii was required for patients undergoing TMZ treatment during the concomitant phase.
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patients with methylated MGMT benefited significantly when treated 
with TMZ alone rather than radiotherapy, whereas patients with 
an unmethylated MGMT gene promoter treated with TMZ alone 
fared worse[6,8]. The National Cancer Institute of Canada (NCIC) 
and European Organisation for Research and Treatment of Cancer 
(EORTC) are currently conducting a phase III trial to evaluate a short 
course of radiotherapy alone administered over 3 weeks versus the 
combination of the same course of radiotherapy with TMZ in patients 
over 65 years of age that are not candidates to undergo the standard 
chemoradiotherapy with TMZ (clinicaltrials.gov: NCT00482677).
Novel Targeted Therapies for
Glioblastoma
Antiangiogenesis
      Vascular epithelial growth factor-A (VEGF-A) is a major regulator 
of angiogenesis and can be detected in high amounts in GBM[9]. It 
plays a critical role in endothelial cell proliferation in GBM[9]. Vascular 
epithelial growth factor receptor-2 (VEGFR-2) is overexpressed by 
3- to 5-fold in tumor endothelial cells compared to that in normal 
endothelial tissue[10]. Overproduction of VEGF may explain, in 
part, dysfunction of the blood-brain barrier as well as edema and 
hemorrhagic areas in GBM[11]. 
      Therapies targeting VEGF have been widely tested in clinical 
trials in GBM patients (Table 1). Cediranib (Recentin™, AstraZeneca, 
Wilmington, DE, USA) is a small-molecule tyrosine kinase inhibitor 
that targets VEGFR. In a randomized, 3-arm phase III trial of 
recurrent GBM, lomustine alone showed a similar progression-free 
survival (PFS) rate to cediranib alone [hazard ratio (HR) = 1.05; 95% 
confidence interval (CI), 0.74 to 1.50; P = 0.90] or to dual treatment 
with cediranib and lomustine (HR = 0.76; 95% CI, 0.53 to 1.08; P = 
0.16)[12]. Moreover, cediranib was associated with increased tumor 
infiltration in a phase II trial in recurrent GBM[13]. Aflibercept (Zaltrap, 
Sanofi and Regeneron Pharmaceuticals, Tarrytown, NY, USA), a 
recombinant fusion protein, is able to bind to and sequester VEGF-A, 
VEGF-B, and placental growth factor (PGF). In a phase II study, 
the objective response rate (ORR) of recurrent GBM patients to 
aflibercept was reported at 24%, whereas the 6-month PFS rate was 
only 7.7%, suggesting minimal antitumor activity of the compound[14]. 
      Bevacizumab (Bev; Avastin®, Roche Basel, Switzerland) is a 
humanized monoclonal antibody directed against VEGF. Several 
trials aimed at studying the effects of Bev, either alone or in 
combination with chemotherapeutic agents, have been performed. 
Two studies led to the conditional approval of Bev by the US Food 
& Drug Administration (FDA). In a phase II study of 35 patients, 
in combination with the topoisomerase I inhibitor irinotecan, Bev 
showed a 6-month PFS rate of 46% and a median OS of 42 weeks, 
and 11% of the patients were alive after 4 years[15,16]. In a randomized 
phase II trial that included 167 patients with recurrent glioblastoma, 
the irinotecan-Bev arm showed a 6-month PFS rate of 50.3% and 
a median OS of 8.9 months; in the Bev only arm, the results were 
similar, with a 6-month PFS rate of 42.6% and a median OS of 9.3 
months[17]. In contrast to the United States, the European Medicines 
Agency (EMA) rejected the approval of Bev based on the lack of 
controlled data. The results of the Avaglio and Radiation Therapy 
Oncology Group (RTOG) 0825 trials were presented at the 2013 
Annual Meeting of the American Society of Clinical Oncology 
(ASCO)[15,18]. Both phase III studies evaluated the addition of 
Bev to standard radiotherapy and TMZ compared with standard 
chemoradiotherapy alone in patients with newly diagnosed GBM. 
Both the Avaglio and RTOG trials, which enrolled 921 and 637 GBM 
patients, respectively, showed an increase in PFS from 6.2 to 10.6 
months (P ≤  0.001) and from 7.3 to 10.7 months (considered non-
significant as it did not meet the prespecified difference), respectively. 
In contrast, median OS was not significantly different (16.8 vs. 16.7 
months in the Avaglio trial and 15.7 vs. 16.1 months in the RTOG 
trial, P > 0.05). Interestingly, although the Avaglio trial suggested 
more favorable quality of life outcomes in patients treated with Bev, 
the RTOG 0825 trial suggested that patients under Bev treatment 
Table 1. MicroRNAs (miRNAs) associated with epithelial-mesenchymal transition (EMT)
Agent Class Target Clinical trials Comments
Bevacizumab Anti-VEGF antibody VEGF Phase II, recurrent;
phase II & III, initial
Approved by the US FDA and
Swissmedic for recurrent GBM
Cediranib (Recentin) Small-molecule VEGFR, PDGFR,
FGFR1, c-KIT
Phase I & II, initial;
phase III, recurrent
No effect in a multicentric
phase III study
Vatalanib (PTK787) Small-molecule VEGFR, c-KIT,
PDGFR
Phase I & II, initial
and recurrent
Minimal efficacy
Aflibercept Protein, 97 kDa VEGF Trap Phase I & II, initial
and recurrent 
Minimal efficacy
Cilengitide Peptide Alphav integrin inhibitor, 
antiangiogenesis
Phase II & III Phase III trial in newly diagnosed
GBM showed no efficacy
VEGF, vascular epithelial growth factor; VEGFR, vascular epithelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; FGFR1, 
fibroblast growth factor receptor 1; FDA, Food & Drug Administration; GBM, glioblastoma multiforme.
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showed a significantly worse neurocognitive outcome.
      In summary, VEGF- or VEGFR-targeted treatments have failed to 
demonstrate a benefit in OS in patients with GBM. The discrepancy 
between improved PFS and unchanged OS that was observed in 
most trials targeting VEGF inhibition has raised some questions. 
It has been postulated that antiangiogenic agents can transiently 
“normalize” the abnormal structure and function of tumor vasculature, 
improving its efficiency to deliver blood and oxygen and reducing 
intratumoral fluid pressure (IFP) and peritumoral edema. This 
aspect is certainly important to reduce edema-induced neurologic 
deficits and allows for the reduction or replacement of steroid 
treatments. It has also been postulated that this might improve drug 
delivery to the tumor. To date, however, combination treatments 
with chemotherapeutic and antiangiogenic agents have not 
resulted in improved survival in comparison to treatment with single 
antiangiogenic agents[17,19-21]. Experiments in animal models have 
suggested that Bev may affect tumor cell invasion. In a xenograft 
model using the GBM U87MG cell line, Bev treatment resulted in an 
increased invasiveness of tumor cells[22]. Initially, it was suggested 
that this increased invasiveness was observed frequently[23]; however, 
this has not been confirmed in a large review analyzing patterns of 
progression following treatment with Bev[24].
Inhibition of integrins
      Integrins are heterodimeric transmembrane cell surface 
receptors that play a major role in the interaction between the cell 
and its surrounding stroma. They regulate some key processes 
such as cell adhesion, differentiation, proliferation, survival, control 
of inflammation, and modulation of signaling pathways including 
platelet-derived growth factor (PDGF), epidermal growth factor 
(EGF), and VEGF. The members of the integrin family alphaVbeta3 
and alphaVbeta5 are overexpressed in both the tumor cells and 
the vasculature of GBM. Cilengitide (Merck KGaA, Darmstadt, 
Germany) is a selective inhibitor of these integrins and has been 
extensively evaluated in GBM. Patients with MGMT gene promoter 
methylation appeared to derive the greatest benefit. Several phase 
II studies have suggested a more favorable outcome in patients 
treated with higher doses of cilengitide in recurrent GBM as well as 
a favorable comparison with historical controls with newly diagnosed 
GBM (especially those with methylated MGMT)[25-27]. Based on 
these findings, a large phase III trial was initiated by Merck in 
collaboration with the EORTC in patients with newly diagnosed GBM 
and MGMT promoter methylation. No activity for cilengitide could be 
demonstrated in this trial, and further development of the compound 
was discontinued.
Inhibition of growth factor receptors and
intracellular signaling pathways
      Amplification and overexpression of epidermal growth factor 
receptor (EGFR) are observed in approximately 50% of GBM 
cases[28]. Several compounds directed against EGFR function have 
been evaluated (Table 2). For instance, gefitinib (Iressa; AstraZeneca, 
Wilmington, DE, USA) induced a partial response in 12.7% of 
recurrent GBM cases in a phase II study[29]. However, the 6-month 
PFS rate was merely 13%, and the median OS was 10 months, which 
is identical to the expected outcome in GBM patients undergoing 
non-efficient therapies[29,30]. When associated with radiotherapy, 
TMZ, or other agents, erlotinib (Tarceva, Genentech and OSI 
pharmaceuticals, Long Island, NY, USA), another EGFR inhibitor, 
also failed to show any positive effect on PFS and OS in patients with 
recurrent or newly diagnosed GBM[31]. Despite adequate distribution 
into tumor tissue, lapatinib (Tyverb, GlaxoSmithKline, Brentford, 
United Kingdom), a dual HER2 and EGFR inhibitor, failed to show 
any efficacy in a phase II trial[32]. The chimeric monoclonal antibody 
cetuximab, which inhibits EGFR, also showed minimal efficacy, even 
when patients were stratified according to the amplification of EGFR 
Table 2. Selected targeted agents evaluated in GBM patients
EGFR, epidermal growth factor receptor; PKC, protein kinase C; PI3K/AKT, phosphatidylinositide 3-kinase/protein kinase B; mTOR, mammalian 
target of rapamycin. Other abbreviations as in Table 1.
Agent Class Target Clinical trials Comments
Erlotinib (Tarceva) Small-molecule EGFR Phase II, initial and recurrent Minimal efficacy 
Gefitinib (Iressa) Small-molecule EGFR Phase II, recurrent Minimal efficacy 
Lapatinib (Tyverb) Small-molecule EGFR, ErbB2 Phase II, recurrent No efficacy
Cetuximab Chimeric antibody EGFR Phase I & II, initial and
recurrent
Minimal efficacy 
Imatinib (Gleevec) Small-molecule PDGFR, c-KIT, BCR-ABL Phase I & II, recurrent Minimal efficacy
Enzastaurin Small-molecule PKC, PI3K/AKT pathway
inhibitor
Phase I, II & III, initial and
recurrent
Limited efficacy. Phase III trial
in recurrent GBM discontinued
early as Enzastraurin was
found inferior to lomustin
Temsirolimus
(Toricel)
Small-molecule mTOR inhibitor Phase I & II, initial and
recurrent
Limited efficacy as single agent
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and when combined with irinotecan and Bev[33,34].
      In the proneural subtype of GBM, platelet-derived growth factor 
receptor (PDGFR) is often activated and overexpressed[35]. Activation 
of the PDGF pathway stimulates GBM growth and angiogenesis[36]. 
Imatinib (Glivec; Novartis, Basel Switzerland) is a kinase inhibitor 
of PDGFR, c-KIT, and the oncogene fusion protein BCR-ABL. 
In a phase II study in recurrent GBM that stratified patients by 
their PDGFR expression, a 6-month PFS rate of merely 3% was 
reported[37]. Several other multicenter trials also failed to show 
efficacy of imatinib alone or in combination with hydroxyurea[38,39].
      As illustrated above, to date, agents targeting a single specific 
pathway have failed to demonstrate consistent improvement in the 
outcome of patients with GBM. This might be due to several reasons. 
First, the selected agents are not sufficient to induce significant 
inhibition. Second, although efficient, the agents are not able to reach 
their target in at a sufficient concentration. The blood-brain barrier, 
intratumoral pressure, and other factors may hinder the therapeutic 
agents to efficiently target and inhibit their pathways in GBM, or 
the size of the molecule (e.g., monoclonal antibodies) may impede 
crossing of the blood-brain barrier. Third, the inhibition obtained by 
these agents is counterbalanced by the activation of other parallel 
pathways that signal downstream of the inhibition. For these 
reasons, a number of compounds that directly target downstream 
effectors have been evaluated. For instance, mammalian target of 
rapamycin (mTOR) transduces signals from phosphatidylinositide 
3-kinase/protein kinase B (PI3K/AKT) as well as the Ras pathway. 
mTOR expression is increased by overexpression of growth factors 
or phosphatase and tensin homolog deleted on chromosome ten 
(PTEN)[28]. 
      Several selective inhibitors of mTOR have been evaluated 
without clear efficacy. In a phase II study, temsirolimus (Rapamune; 
Wyeth, now Pfizer, New York, NY, USA) showed little to no activity as 
a single agent[40] or when combined with erlotinib[41]. The combination 
of temsirolimus with Bev also did not produce any significant effects 
as none of the 10 patients in the study showed a radiological 
response, resulting in the premature termination of the study[42]. The 
combination of temsirolimus and sorafenib also did not associate with 
improved outcome[43]. 
      Protein kinase C (PKC), when activated, contributes to the 
propagation of some growth factors, including EGF and PDGF. 
Enzastaurin (Eli Lilly, Indiana, ID, USA) is a specific PKC inhibitor. 
Initial, unpublished reports suggested significant activity of 
enzastaurin in recurrent GBM, with a radiological response rate of 
22% and a promising PFS. However, a subsequent randomized 
phase II/III study failed to confirm this efficacy[44]. Similarly, the 
anti-estrogen drug tamoxifen, which also targets PKC, has been 
evaluated in GBM without significant activity[45,46]. 
      Epigenetic modifications of genes also play a key role in 
the malignant transformation of glioma cells. Acetylation and 
deacetylation (HDACs) of histones is a fundamental mechanism 
of gene regulation. It has long been suggested that valproic acid, 
which has been shown to inhibit HDACs at high concentrations, may 
improve survival in patients with GBM. A retrospective subgroup 
analysis of patients included in the seminal EORTC/NCIC 26981-
22981 trial that underwent valproic acid treatment at inclusion showed 
a significantly better outcome than patients that did not undergo any 
antiepileptic treatment (HR = 0.67, 95% CI = 0.49-0.93) or those 
treated with an enzyme-inducing antiepileptic agent (HR = 0.69, 95% 
CI = 0.53-0.90), although these patients showed more hematologic 
adverse events[47]. These findings could not be confirmed in the phase 
III Cilengitide trial (Prof. Roger Stupp, personal communication). 
Immunotherapy for the treatment of GBM
      Modulating the immune system has been considered a promising 
modality for cancer treatment in various malignancies. Recent data 
demonstrate that treatment with the monoclonal antibody ipilimumab 
results in the modulation of T lymphocytes and restores immune 
response against melanoma cells[48]. The sipuleucel-T vaccine was 
also approved by the US FDA for treatment of prostate cancer[49]. A 
number of approaches are also under investigation for GBM, including 
the use of autologous stimulated lymphocytes, immunotherapy with 
cytokines and dendritic cells, and tumor- or peptide-based vaccines. 
One such vaccine is rindopepimut, a peptide-based vaccine against a 
13 amino-acid sequence of the tumor-specific antigen EGFRvIII. This 
mutant variant of EGFR is constitutively activated and expressed 
in approximately 30% of GBM patients. Two phase II trials have 
evaluated rindopepimut in patients with newly diagnosed GBM. 
Patients who had completed radiotherapy and concomitant TMZ 
were enrolled to undergo maintenance TMZ treatment along with a 
rindopepimut vaccination. In these studies, the median PFS was 14.2 
months (95% CI: 9.9 to 17.6 months) and 15.2 months (95% CI: 11.0 
to 18.5 months), whereas the median OS was 23.6 and 26 months, 
respectively[50,51]. These data are encouraging, but as patients 
were only enrolled after completion of the radiotherapy, cross trial 
comparisons with the landmark trial by Stupp et al.[1] cannot be made. 
A multicenter, randomized, double-blinded study is currently ongoing 
to confirm the validity of this approach (NCT01480479). 
Alternating electric fields
      Alternating electric fields (AEF) have been shown to have a wide 
range of effects on living tissues. At very low frequencies (<1 kHz), 
AEF can induce membrane depolarization and stimulate excitable 
tissues. Low intensity-intermediate frequency AEF (100-300 kHz) 
has been shown to arrest the proliferation and differentiation of cells, 
resulting in a variety of cancer cell lines both in vitro and in vivo[52]. 
After exposure to AEF, abnormal mitotic configurations that closely 
resemble morphologic abnormalities were observed with agents 
that interfere with microtubule polymerization, such as paclitaxel[53]. 
It has been postulated that non-homogeneous electric fields 
generate unidirectional forces that disrupt the normal polymerization-
depolymerization process of tubulin during mitosis[52]. 
      Two clinical trials have evaluated the potential effects of AEF 
in patients with recurrent GBM using the NovoTTF-100A device 
(Novocure Ltd, Haifa, Israel). This battery-operated device generates 
AEF with a frequency of 200 kHz and an intensity of 1-2 V/cm. In 
the first trial[52], 10 patients were enrolled and were required to wear 
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the device continuously for a minimum of 18 h/day until disease 
progression (or up to 18 months). The device was well tolerated, 
as the major adverse events were limited to dermatitis beneath the 
electrodes. The time-to-progression (TTP) was 6.1 months; the 
6-month PFS rate was 50%, and the median OS was 62.2 weeks, 
which compared favorably with historical controls that showed a TTP 
of 9.5 weeks, a 6-month PFS rate of 15.3%, and a median OS of 29.3 
weeks[52]. 
      Based on these results, a multicenter phase III trial was initiated 
to compare the safety and efficacy of NovoTTF-100A with physician’s 
choice chemotherapy in 238 patients with recurrent GBM. In that 
study, the majority of patients had undergone at least 1 prior therapy 
for recurrence. There was no significant difference in OS between the 
groups (6.0 vs. 6.6 months, P = 0.23), suggesting that this treatment 
was not inferior to chemotherapy in heavily pretreated patients with 
recurrent GBM or that neither standard best physician’s choice 
chemotherapy nor the TTF device has a substantial antitumor effect 
in this population. The definite confirmation of efficacy of NovoTTF-
100A will be obtained by an ongoing multicenter phase III trial that 
randomizes over 800 patients with newly diagnosed GBM to undergo 
standard radiotherapy with concomitant and adjuvant TMZ versus 
standard radiotherapy plus NovoTTF and adjuvant TMZ treatment. 
Preliminary studies indicated that AEF acted synergistically with 
chemotherapeutic agents on human glioma cell line U-118. In a pilot 
study of 10 newly diagnosed GBM patients treated with NovoTTF at 
the initiation of adjuvant TMZ, a median PFS of 36.2 months and a 
median OS of 39 months were observed[54]. In comparison, patients 
of the pivotal EORTC trial (n = 81) who initiated maintenance TMZ 
showed a median PFS of 17.51 months (95% CI: 12.75 to 19.88 
months) and a median OS of 26.94 months (95% CI: 22.60 months 
to not reached) (Dr. Thierry Gorlia, personal communication). 
Conclusions
      The prognosis of GBM remains poor despite aggressive 
management including neurosurgical resection, radiation, and 
chemotherapy. A number of challenges remain to achieve better 
tumor control and patient survival. GBMs present a complex 
heterogeneity at the genomic and differentiation levels. It is therefore 
not surprising that targeted therapies have so far failed to deliver 
a clear clinical benefit. This might be the result of multiple driver 
mutations in different tumor cell populations within the same tumor. 
Therefore, combinations of multiple inhibitors have been proposed 
along with the identification of key driver mutations that are specific 
to each patient. A specific molecular profiling could therefore result 
in specific selection of targeted agents for every patient. To date, this 
approach is however still limited by the lack of effective therapies.
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